LUMOS DIAGNOSTICS HOLDINGS ORD

Lumos Diagnostics (ASX: LDX) has achieved complete US Medicare reimbursement recognition for its FebriDx point-of-care diagnostic test, securing coverage from all seven Medicare Administrative Contractors.

Lumos Diagnostics (ASX: LDX) has received significant US financial backing for its development of unique point-of-care diagnostic test technology. Lumos has been awarded approximately $4.3 million by a division of the US government’s health division to support a planned study and regulatory submission for the company’s FebriDx bacterial/non-bacterial test. FebriDx is designed to assess whether […]

Lumos Diagnostics (ASX: LDX) has extended a distribution agreement for its FebriDx rapid point-of-care test to include the Belgian market of US healthcare products supplier Henry Schein Medical. FebriDx is designed to identify viral versus bacterial acute respiratory infections within 10 minutes from a fingerstick blood sample and can be used to help accurately manage […]

Lumos Diagnostics (ASX: LDX) has received a second US$5 million payment from women’s health firm Hologic Inc under an intellectual property (IP) agreement signed between the two companies in January. The agreement grants Hologic an exclusive licence to use Lumos’ proprietary reader and point-of-care technologies in the development of its fetal fibronectin (fFN) test targeting […]